Technology & Telecommunication Services » Networking | Young In Frontier Co. Ltd.

Young In Frontier Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
3,857
4,065
3,934
8,052
18,026
Total Accounts Receivable
1,757
1,846
2,487
3,489
3,337
Inventories
4,154
4,792
5,898
5,981
7,389
Other Current Assets
71
30
23
37
485
Total Current Assets
9,839
10,734
12,343
17,559
29,237
Net Property, Plant & Equipment
3,929
3,683
3,816
3,614
3,442
Total Investments and Advances
5,637
5,664
5,643
5,510
220
Long-Term Note Receivable
-
20
20
-
-
Intangible Assets
367
229
170
5
2
Other Assets
12
-
-
42
45
Total Assets
19,784
20,330
21,991
26,729
32,962
ST Debt & Current Portion LT Debt
-
-
392
-
-
Accounts Payable
1,364
2,089
2,545
2,895
4,037
Income Tax Payable
110
40
197
306
367
Other Current Liabilities
803
545
656
884
1,635
Total Current Liabilities
2,277
2,674
3,789
4,086
6,038
Provision for Risks & Charges
898
898
-
-
-
Deferred Taxes
-
-
-
-
16
Other Liabilities
1,226
1,132
1,083
1,074
1,074
Total Liabilities
4,401
4,704
4,872
5,160
7,112
Common Equity (Total)
15,383
15,626
17,119
21,570
25,849
Total Shareholders' Equity
15,383
15,626
17,119
21,570
25,849
Total Equity
15,383
15,626
17,119
21,570
25,849
Liabilities & Shareholders' Equity
19,784
20,330
21,991
26,729
32,962

About Young In Frontier Co.

View Profile
Address
Unit 1101, 11th Floor, Tower 5
Seoul SL 08513
Korea, Republic Of
Employees -
Website http://www.younginfrontier.com
Updated 09/14/2018
YOUNG IN FRONTIER Co., Ltd. engages in development of antibodies and antibody drugs and provision of scientific technology products and services. It operates through the bio and scientific instrument business divisions. The bio business division offers antibodies for research and development and antibody drugs for treatment of incurable diseases and genetic disorders.